July 15, 2008

Johnson & Johnson Reports 2008 Second-Quarter Results:

Sales of $16.5 Billion Increased 8.7% Versus a Year Ago; EPS was $1.17 Excluding 2008 Special Items, Second-Quarter EPS of $1.18 Increased 12.4%*

NEW BRUNSWICK, N.J., July 15, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson today announced record sales of $16.5 billion for the second quarter of 2008, an increase of 8.7% as compared to the second quarter of 2007. Operational growth was 3.1% and the positive impact of currency was 5.6%. Domestic sales were up 2.1%, while international sales increased 16.2%, reflecting operational growth of 4.3% and a positive currency impact of 11.9%.

Net earnings and diluted earnings per share for the second quarter of 2008 were $3.3 billion and $1.17, respectively. The second quarter of 2008 included an after-tax in-process research and development charge of $40 million associated with the acquisition of Amic, a developer of in vitro diagnostic technologies for use in Point-of-Care and near-patient settings. Excluding this charge, net earnings for the quarter of $3.4 billion and diluted earnings per share of $1.18 represent increases of 9.3% and 12.4 %, respectively, as compared to the same period in 2007.* The Company increased its earnings guidance for full-year 2008 to $4.45 - $4.50 per share, which does not include the impact of any in-process research and development charges or other special items.

"Our solid earnings this quarter build on our strong track record of performance," said William C. Weldon, Chairman and Chief Executive Officer. "We are successfully managing through short-term pressures while continually making progress to enhance our long-term growth."

Worldwide Medical Devices and Diagnostics sales of $6.1 billion for the second quarter represented a 12.1% increase over the prior year with operational growth of 5.7% and a positive impact from currency of 6.4%. Domestic sales increased 4.0%, while international sales increased 19.7%; 7.3% from operations and 12.4% from currency.

Primary contributors to the operational growth included Ethicon Endo-Surgery's minimally invasive products; DePuy's orthopaedic joint reconstruction, sports medicine and trauma businesses; Ethicon's surgical care products; Vistakon's disposable contact lenses; and Diabetes Care's blood glucose monitoring and insulin delivery products.

On July 1, 2008, the Company announced it received clearance of its ONETOUCH PING Glucose Management System by the U.S. Food and Drug Administration (FDA), the first full-feature insulin pump that wirelessly communicates with a blood glucose meter-remote.

Worldwide Consumer sales of $4.0 billion for the second quarter represented a 13.2% increase over the prior year with operational growth of 6.8% and a positive impact from currency of 6.4%. Domestic sales increased 8.5%, while international sales increased 17.0%; 5.6% from operations and 11.4% from currency.

Sales results reflect the strong performance of the U.S. launch of ZYRTEC, an over-the-counter allergy treatment; LISTERINE antiseptic mouthrinse and whitening products; Baby Care products; and the skin care lines of NEUTROGENA, CLEAN & CLEAR, and AVEENO.

During the quarter, the Company received FDA approval of EVOLENCE, a new advanced collagen-based structural dermal filler for the correction of moderate to deep facial wrinkles and folds.

Worldwide Pharmaceutical sales of $6.3 billion for the second quarter represented an increase over the prior year of 3.1% with an operational decline of 1.3% and a positive impact from currency of 4.4%. Domestic sales decreased 1.7%, while international sales increased 11.3%, which reflected an operational decline of 0.6% and a positive currency impact of 11.9%.

Sales growth reflects the strong performance of TOPAMAX, an antiepileptic and a treatment for the prevention of migraine headaches; VELCADE, a treatment for multiple myeloma; RISPERDAL CONSTA, an antipsychotic medication; and REMICADE in the U.S., a biologic approved for the treatment of a number of immune mediated inflammatory diseases.

Growth was negatively impacted by lower sales of PROCRIT, a product for the treatment of anemia, due to a decline in the market. Sales results of RISPERDAL Oral, an antipsychotic medication, were negatively impacted by generic competition outside the U.S. and slowing sales ahead of the loss of marketing exclusivity on June 29, 2008, in the U.S. On June 30, 2008, the Company announced the launch of an authorized generic version of RISPERDAL Oral.

During the quarter, the Company announced that it received FDA approval of its Supplemental New Drug Application (sNDA) for CONCERTA, for the treatment of Attention Deficit Hyperactivity Disorder in adults. In addition, the Company submitted a Biologics License Application to the FDA requesting the approval of golimumab (CNTO 148) as a monthly subcutaneous treatment for adults with active forms of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. The Company also filed an sNDA requesting pediatric exclusivity for TOPAMAX.

About Johnson & Johnson

Caring for the world, one person at a time ... inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our 120,200 employees at more than 250 Johnson & Johnson companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

* Net earnings and diluted earnings per share excluding special items, such as after-tax in-process research and development charges, are non-GAAP financial measures and should not be considered replacements for GAAP results. For a reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures, see the accompanying tables to this release.

NOTE TO INVESTORS

Johnson & Johnson will conduct a conference call with financial analysts to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com. A replay and podcast will be available approximately two hours after the live webcast by visiting www.investor.jnj.com.

Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm. The schedules include supplementary sales data, a condensed consolidated statement of earnings, and sales of key products/franchises. Additional information on Johnson & Johnson can be found on the Company's website at www.jnj.com.

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Johnson & Johnson's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of the Company's Annual Report on Form 10-K for the fiscal year ended December 30, 2007. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.)


    Johnson & Johnson and Subsidiaries
    Supplementary Sales Data

    (Unaudited; Dollars in Millions)
                                        SECOND QUARTER

                                                      Percent Change
                             2008      2007     Total    Operations   Currency
    Sales to customers by
    segment of business

    Consumer
      U.S.                  $1,694     1,562      8.5%        8.5          -
      International          2,342     2,002      17.0        5.6       11.4
                             4,036     3,564      13.2        6.8        6.4

    Pharmaceutical
      U.S.                   3,793     3,860      (1.7)      (1.7)         -
      International          2,547     2,289      11.3       (0.6)      11.9
                             6,340     6,149       3.1       (1.3)       4.4

    Med Devices & Diagnostics
      U.S.                   2,723     2,619       4.0        4.0          -
      International          3,351     2,799      19.7        7.3       12.4
                             6,074     5,418      12.1        5.7        6.4

    U.S.                     8,210     8,041       2.1        2.1          -
    International            8,240     7,090      16.2        4.3       11.9
    Worldwide              $16,450    15,131      8.7%        3.1        5.6


    (Unaudited; Dollars in Millions)
                                                SIX MONTHS
                                                      Percent Change
                             2008      2007    Total    Operations    Currency
    Sales to customers by
    segment of business

    Consumer
      U.S.                   3,513     3,191      10.1%      10.1          -
      International          4,587     3,869      18.6        7.0       11.6
                             8,100     7,060      14.7        8.3        6.4

    Pharmaceutical
      U.S.                   7,863     7,894      (0.4)      (0.4)         -
      International          4,906     4,476       9.6       (1.8)      11.4
                            12,769    12,370       3.2       (0.9)       4.1

    Med Devices & Diagnostics
      U.S.                   5,311     5,203       2.1        2.1          -
      International          6,464     5,535      16.8        5.0       11.8
                            11,775    10,738       9.7        3.6        6.1

    U.S.                    16,687    16,288       2.4        2.4          -
    International           15,957    13,880      15.0        3.4       11.6
    Worldwide              $32,644    30,168      8.2%        2.8        5.4



    Johnson & Johnson and Subsidiaries
    Supplementary Sales Data

    (Unaudited; Dollars in Millions)             SECOND QUARTER

                                                       Percent Change
                               2008     2007    Total    Operations   Currency
    Sales to customers by
    geographic area
    U.S.                     $8,210    8,041     2.1%       2.1            -

    Europe                    4,547    3,907    16.4        2.4         14.0
    Western Hemisphere
     excluding U.S.           1,280    1,131    13.2        3.3          9.9
    Asia-Pacific, Africa      2,413    2,052    17.6        8.5          9.1
    International             8,240    7,090    16.2        4.3         11.9

    Worldwide               $16,450   15,131     8.7%       3.1          5.6


    (Unaudited; Dollars in Millions)                  SIX MONTHS
                                                      Percent Change
                               2008     2007    Total   Operations   Currency

    Sales to customers by
    geographic area
    U.S.                    $16,687   16,288      2.4%      2.4            -

    Europe                    8,855    7,720     14.7       1.6         13.1
    Western Hemisphere
     excluding U.S.           2,525    2,177     16.0       4.7         11.3
    Asia-Pacific, Africa      4,577    3,983     14.9       5.9          9.0
    International            15,957   13,880     15.0       3.4         11.6

    Worldwide               $32,644   30,168      8.2%      2.8          5.4



    Johnson & Johnson and Subsidiaries
    Condensed Consolidated Statement of Earnings

    (Unaudited; in Millions Except
     Per Share Figures)                     SECOND QUARTER

                               2008                  2007             Percent
                                    Percent                Percent   Increase
                          Amount   to Sales    Amount     to Sales  (Decrease)

    Sales to customers   $16,450      100.0    $15,131       100.0        8.7
    Cost of products
     sold                  4,751       28.9      4,358        28.8        9.0
    Selling, marketing
     and administrative
     expenses              5,507       33.5      5,029        33.3        9.5
    Research expense       1,896       11.5      1,866        12.3        1.6
    In-process research
     & development            40        0.2          -           -
    Interest (income)
     expense, net             16        0.1        (36)       (0.2)
    Other (income)
     expense, net           (135)      (0.8)      (117)       (0.8)
    Earnings before
     provision for taxes
     on income             4,375       26.6      4,031        26.6        8.5
    Provision for taxes
     on income             1,048        6.4        950         6.2       10.3
    Net earnings          $3,327       20.2     $3,081        20.4        8.0


    Net earnings per
     share (Diluted)       $1.17                 $1.05                   11.4

    Average shares
     outstanding
     (Diluted)           2,844.8               2,922.5

    Effective tax rate      24.0%                 23.6%

    Adjusted earnings
     before provision
     for taxes and net
     earnings
      Earnings before
       provision for
       taxes on income    $4,415(1)    26.8     $4,031        26.6        9.5
      Net earnings        $3,367(1)    20.5     $3,081        20.4        9.3
      Net earnings per
       share (Diluted)     $1.18(1)              $1.05                   12.4
      Effective tax
       rate                 23.7%                 23.6%


    (1) The difference between as reported earnings before provision for taxes
    on income and net earnings and net earnings per share (diluted) is IPR&D
    of $40 million with no tax benefit and $0.01 per share, respectively.



    Johnson & Johnson and Subsidiaries
    Condensed Consolidated Statement of Earnings

    (Unaudited; in Millions
     Except Per Share Figures)            SIX MONTHS

                               2008                 2007              Percent
                                  Percent                Percent     Increase
                         Amount  to Sales     Amount    to Sales    (Decrease)

    Sales to customers  $32,644     100.0    $30,168       100.0        8.2
    Cost of products
     sold                 9,365      28.7      8,743        29.0        7.1
    Selling, marketing and
     administrative
     expenses            10,630      32.6      9,831        32.5        8.1
    Research expense      3,608      11.1      3,518        11.7        2.6
    In-process research
     & development           40       0.1        807         2.7
    Interest (income)
     expense, net            32       0.1        (69)       (0.2)
    Other (income)
     expense, net          (153)     (0.5)      (345)       (1.1)
    Earnings before
     provision for taxes
     on income            9,122      27.9      7,683        25.4       18.7
    Provision for taxes
     on income            2,197       6.7      2,029         6.7        8.3
    Net earnings         $6,925      21.2     $5,654        18.7       22.5

    Net earnings per
     share (Diluted)      $2.43                $1.93                   25.9

    Average shares
     outstanding
     (Diluted)          2,856.1              2,924.9

    Effective tax rate     24.1%                26.4%

    Adjusted earnings
     before provision for
     taxes and net earnings
    Earnings before
     provision for taxes
     on income           $9,162(1)   28.1     $8,490(2)     28.1        7.9
    Net earnings         $6,965(1)   21.3     $6,461(2)     21.4        7.8
    Net earnings per
     share (Diluted)      $2.44(1)             $2.21(2)                10.4
    Effective tax rate     24.0%                23.9%

    (1) The difference between as reported earnings before provision for taxes
    on income and net earnings and net earnings per share (diluted) is IPR&D
    of $40 million with no tax benefit and $0.01 per share, respectively.

    (2) The difference between as reported earnings before provision for taxes
    on income and net earnings and net earnings per share (diluted) is IPR&D
    of $807 million with no tax benefit and $0.28 per share, respectively.



                       REPORTED SALES vs. PRIOR PERIOD
                                     $MM


                                             SECOND QUARTER

                                                      % Change

                        2008       2007   Reported  Operational (1)   Currency

    PHARMACEUTICAL
     SEGMENT (2) (3)

    ACIPHEX/PARIET
    US                   153        161      -5.0%       -5.0%             -
    Intl                 172        175      -1.7%      -11.8%         10.1%
    WW                   325        336      -3.3%       -8.6%          5.3%

    CONCERTA
    US                   208        199       4.5%        4.5%             -
    Intl                  71         57      24.6%       12.6%         12.0%
    WW                   279        256       9.0%        6.3%          2.7%

    DURAGESIC/FENTANYL
     TRANSDERMAL
    US                    70         96     -27.1%      -27.1%             -
    Intl                 202        192       5.2%       -6.6%         11.8%
    WW                   272        288      -5.6%      -13.5%          7.9%

    LEVAQUIN/FLOXIN
    US                   330        344      -4.1%       -4.1%             -
    Intl                  21         20       5.0%       -0.2%          5.2%
    WW                   351        364      -3.6%       -3.9%          0.3%

    PROCRIT/EXPREX
    US                   346        449     -22.9%      -22.9%             -
    Intl                 306        309      -1.0%      -12.7%         11.7%
    WW                   652        758     -14.0%      -18.8%          4.8%

    RAZADYNE/REMINYL
    US                    42         51     -17.6%      -17.6%             -
    Intl                 110         81      35.8%       19.7%         16.1%
    WW                   152        132      15.2%        5.4%          9.8%

    REMICADE
    US                   684        625       9.4%        9.4%             -
    US Exports (4)       200        244     -18.0%      -18.0%             -
    Intl                   2          -     100.0%      100.0%             -
    WW                   886        869       2.0%        2.0%             -

    RISPERDAL
    US                   492        540      -8.9%       -8.9%             -
    Intl                 220        308     -28.6%      -36.6%          8.0%
    WW                   712        848     -16.0%      -18.9%          2.9%

    RISPERDAL CONSTA
    US                   120        102      17.6%       17.6%             -
    Intl                 223        176      26.7%       12.2%         14.5%
    WW                   343        278      23.4%       14.2%          9.2%

    TOPAMAX
    US                   548        472      16.1%       16.1%             -
    Intl                 129        106      21.7%        9.3%         12.4%
    WW                   677        578      17.1%       14.8%          2.3%

    VELCADE
    US                     1          1          -           -             -
    Intl                 204        125      63.2%       47.0%         16.2%
    WW                   205        126      62.7%       46.8%         15.9%

    OTHER
    US                   599        576       4.0%        4.0%             -
    Intl                 887        740      19.9%        5.0%         14.9%
    WW                 1,486      1,316      12.9%        4.5%          8.4%

    TOTAL PHARMACEUTICAL
    US                 3,793      3,860      -1.7%       -1.7%             -
    Intl               2,547      2,289      11.3%       -0.6%         11.9%
    WW                 6,340      6,149       3.1%       -1.3%          4.4%


                                        SIX MONTHS

                                                      % Change

                         2008     2007    Reported  Operational (1)  Currency

    PHARMACEUTICAL
     SEGMENT (2) (3)

    ACIPHEX/PARIET
    US                    269      320      -15.9%       -15.9%           -
    Intl                  333      352       -5.4%       -15.7%       10.3%
    WW                    602      672      -10.4%       -15.8%        5.4%

    CONCERTA
    US                    432      399        8.3%         8.3%           -
    Intl                  137      109       25.7%        13.7%       12.0%
    WW                    569      508       12.0%         9.4%        2.6%

    DURAGESIC/FENTANYL
     TRANSDERMAL
    US                    145      212      -31.6%       -31.6%           -
    Intl                  360      379       -5.0%       -15.3%       10.3%
    WW                    505      591      -14.6%       -21.2%        6.6%

    LEVAQUIN/FLOXIN
    US                    804      803        0.1%         0.1%           -
    Intl                   43       40        7.5%         2.0%        5.5%
    WW                    847      843        0.5%         0.2%        0.3%

    PROCRIT/EXPREX
    US                    680      979      -30.5%       -30.5%           -
    Intl                  601      596        0.8%       -11.1%       11.9%
    WW                  1,281    1,575      -18.7%       -23.2%        4.5%

    RAZADYNE/REMINYL
    US                     92      102       -9.8%        -9.8%           -
    Intl                  209      158       32.3%        16.8%       15.5%
    WW                    301      260       15.8%         6.4%        9.4%

    REMICADE
    US                  1,360    1,225       11.0%        11.0%           -
    US Exports (4)        520      375       38.7%        38.7%           -
    Intl                    4        -      100.0%       100.0%           -
    WW                  1,884    1,600       17.8%        17.8%           -


    RISPERDAL
    US                  1,074    1,099       -2.3%        -2.3%           -
    Intl                  447      616      -27.4%       -35.1%        7.7%
    WW                  1,521    1,715      -11.3%       -14.1%        2.8%

    RISPERDAL CONSTA
    US                    221      203        8.9%         8.9%           -
    Intl                  431      336       28.3%        13.9%       14.4%
    WW                    652      539       21.0%        12.0%        9.0%

    TOPAMAX
    US                  1,068      973        9.8%         9.8%           -
    Intl                  255      215       18.6%         6.7%       11.9%
    WW                  1,323    1,188       11.4%         9.3%        2.1%

    VELCADE
    US                      3        3           -            -           -
    Intl                  386      236       63.6%        48.4%       15.2%
    WW                    389      239       62.8%        47.8%       15.0%

    OTHER
    US                  1,195    1,201       -0.5%        -0.5%           -
    Intl                1,700    1,439       18.1%         3.8%       14.3%
    WW                  2,895    2,640        9.7%         1.9%        7.8%

    TOTAL PHARMACEUTICAL
    US                  7,863    7,894       -0.4%        -0.4%           -
    Intl                4,906    4,476        9.6%        -1.8%       11.4%
    WW                 12,769   12,370        3.2%        -0.9%        4.1%


    (1) Operational growth excludes the effect of currency
    (2) Select areas (unaudited)
    (3) Prior year amounts have been reclassified to conform with current
        presentation
    (4) For external purposes, reported as U.S. sales


                                             SECOND QUARTER

                                                      % Change

                          2008      2007    Reported  Operational (1) Currency


    MEDICAL DEVICES AND
     DIAGNOSTICS (2) (3)

    CORDIS (4)
    US                     348       397     -12.3%      -12.3%           -
    Intl                   504       455      10.8%       -1.1%       11.9%
    WW                     852       852       0.0%       -6.4%        6.4%

    DEPUY
    US                     702       663       5.9%        5.9%           -
    Intl                   587       472      24.4%       12.2%       12.2%
    WW                   1,289     1,135      13.6%        8.5%        5.1%

    DIABETES CARE
    US                     338       310       9.0%        9.0%           -
    Intl                   336       286      17.5%        4.1%       13.4%
    WW                     674       596      13.1%        6.7%        6.4%

    ETHICON (5)
    US                     374       351       6.6%        6.6%           -
    Intl                   646       553      16.8%        5.1%       11.7%
    WW                   1,020       904      12.8%        5.7%        7.1%

    ETHICON ENDO-SURGERY
    US                     484       454       6.6%        6.6%           -
    Intl                   640       503      27.2%       13.4%       13.8%
    WW                   1,124       957      17.5%       10.4%        7.1%

    ORTHO-CLINICAL
     DIAGNOSTICS (5)
    US                     250       231       8.2%        8.2%           -
    Intl                   226       190      18.9%        6.3%       12.6%
    WW                     476       421      13.1%        7.4%        5.7%

    VISION CARE
    US                     227       213       6.6%        6.6%           -
    Intl                   412       340      21.2%        9.5%       11.7%
    WW                     639       553      15.6%        8.4%        7.2%

    TOTAL MEDICAL
     DEVICES AND
     DIAGNOSTICS
    US                   2,723     2,619       4.0%        4.0%           -
    Intl                 3,351     2,799      19.7%        7.3%       12.4%
    WW                   6,074     5,418      12.1%        5.7%        6.4%


                                             SIX MONTHS

                                                      % Change

                         2008        2007  Reported  Operational (1)  Currency

    MEDICAL DEVICES
     AND DIAGNOSTICS (2) (3)

    CORDIS (4)
    US                    705         821    -14.1%      -14.1%           -
    Intl                  982         959      2.4%       -8.3%       10.7%
    WW                  1,687       1,780     -5.2%      -11.0%        5.8%

    DEPUY
    US                  1,396       1,341      4.1%        4.1%           -
    Intl                1,146         951     20.5%        8.8%       11.7%
    WW                  2,542       2,292     10.9%        6.1%        4.8%

    DIABETES CARE
    US                    641         602      6.5%        6.5%           -
    Intl                  648         543     19.3%        5.9%       13.4%
    WW                  1,289       1,145     12.6%        6.2%        6.4%

    ETHICON (5)
    US                    715         696      2.7%        2.7%           -
    Intl                1,250       1,082     15.5%        4.0%       11.5%
    WW                  1,965       1,778     10.5%        3.5%        7.0%

    ETHICON ENDO-SURGERY
    US                    913         871      4.8%        4.8%           -
    Intl                1,214         977     24.3%       11.3%       13.0%
    WW                  2,127       1,848     15.1%        8.3%        6.8%

    ORTHO-CLINICAL
     DIAGNOSTICS (5)
    US                    488         464      5.2%        5.2%           -
    Intl                  431         365     18.1%        5.8%       12.3%
    WW                    919         829     10.9%        5.5%        5.4%

    VISION CARE
    US                    453         408     11.0%       11.0%           -

    Intl                  793         658     20.5%        9.3%       11.2%
    WW                  1,246       1,066     16.9%       10.0%        6.9%

    TOTAL MEDICAL DEVICES
     AND DIAGNOSTICS
    US                  5,311       5,203      2.1%        2.1%           -
    Intl                6,464       5,535     16.8%        5.0%       11.8%
    WW                 11,775      10,738      9.7%        3.6%        6.1%


    (1) Operational growth excludes the effect of currency
    (2) Select areas (unaudited)
    (3) Prior year amounts have been reclassified to conform with current
        presentation
    (4) Includes sales of Drug-Eluting Stents for Q2 2008 of $167, $227 and
        $394 million Domestic, International and Worldwide respectively

        Includes sales of Drug-Eluting Stents for Q2 2007 of $209, $234 and
        $443 million Domestic, International and Worldwide respectively

        Includes sales of Drug-Eluting Stents for June YTD 2008 of $336, $458
        and $794 million Domestic, International and Worldwide respectively

        Includes sales of Drug-Eluting Stents for June YTD 2007 of $445, $526
        and $971 million Domestic, International and Worldwide respectively

     (5) Restated to include portion of sales previously reported in the
         "Other" category


                                             SECOND QUARTER

                                                      % Change

                          2008      2007   Reported  Operational (1)  Currency


    CONSUMER SEGMENT (2)

    SKIN CARE
    US                     379       338      12.1%      12.1%            -
    Intl                   460       419       9.8%      -1.1%        10.9%
    WW                     839       757      10.8%       4.7%         6.1%

    BABY CARE
    US                     111       106       4.7%       4.7%            -
    Intl                   461       381      21.0%      10.5%        10.5%
    WW                     572       487      17.5%       9.3%         8.2%

    ORAL CARE
    US                     185       186      -0.5%      -0.5%            -
    Intl                   223       168      32.7%      20.8%        11.9%
    WW                     408       354      15.3%       9.7%         5.6%

    OTC/NUTRITIONALS
    US                     679       584      16.3%      16.3%            -
    Intl                   726       622      16.7%       5.1%        11.6%
    WW                   1,405     1,206      16.5%      10.5%         6.0%

    WOMEN'S HEALTH
    US                     158       163      -3.1%      -3.1%            -
    Intl                   346       300      15.3%       3.3%        12.0%
    WW                     504       463       8.9%       1.1%         7.8%

    WOUND CARE / OTHER
    US                     182       185      -1.6%      -1.6%            -
    Intl                   126       112      12.5%       0.6%        11.9%
    WW                     308       297       3.7%      -0.8%         4.5%

    TOTAL CONSUMER
    US                   1,694     1,562       8.5%       8.5%            -
    Intl                 2,342     2,002      17.0%       5.6%        11.4%
    WW                   4,036     3,564      13.2%       6.8%         6.4%



                                           SIX MONTHS
                                                      % Change

                            2008    2007    Reported  Operational (1) Currency
    CONSUMER SEGMENT (2)

    SKIN CARE
    US                      761       695       9.5%       9.5%           -
    Intl                    918       826      11.1%       0.1%       11.0%
    WW                    1,679     1,521      10.4%       4.4%        6.0%

    BABY CARE
    US                      226       215       5.1%       5.1%           -
    Intl                    879       719      22.3%      11.7%       10.6%
    WW                    1,105       934      18.3%      10.1%        8.2%

    ORAL CARE
    US                      384       389      -1.3%      -1.3%           -
    Intl                    410       324      26.5%      15.3%       11.2%
    WW                      794       713      11.4%       6.3%        5.1%

    OTC/NUTRITIONALS
    US                    1,521     1,239      22.8%      22.8%           -
    Intl                  1,478     1,224      20.8%       8.4%       12.4%
    WW                    2,999     2,463      21.8%      15.7%        6.1%

    WOMEN'S HEALTH
    US                      306       326      -6.1%      -6.1%           -
    Intl                    659       558      18.1%       5.9%       12.2%
    WW                      965       884       9.2%       1.5%        7.7%

    WOUND CARE / OTHER
    US                      315       327      -3.7%      -3.7%           -
    Intl                    243       218      11.5%      -0.3%       11.8%
    WW                      558       545       2.4%      -2.3%        4.7%

    TOTAL CONSUMER
    US                    3,513     3,191      10.1%      10.1%           -
    Intl                  4,587     3,869      18.6%       7.0%       11.6%
    WW                    8,100     7,060      14.7%       8.3%        6.4%

    (1) Operational growth excludes the effect of currency
    (2) Select areas (unaudited)

SOURCE Johnson & Johnson

http://www.jnj.com/

Copyright (C) 2008 PR Newswire. All rights reserved

News Provided by COMTEX


Close window | Back to top

Copyright 2014 Johnson & Johnson

This site is governed solely by applicable U.S laws and governmental regulations. Please see our Privacy Policy. Use of this site constitutes your consent to application of such laws and regulations and to our Privacy Policy.Your use of the information on this site is subject to the terms of our Legal Notice. You should view the News section and the most recent SEC Filings in the Investor section in order to receive the most current information made available by Johnson & Johnson.Contact Us with any questions or search this site for more information.